Molecular Infectious Disease Testing Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

Molecular infectious disease testing involves the detection and identification of pathogens through analysis of nucleic acids such as DNA or RNA, providing faster and more accurate results than traditional culture-based methods. The market spans laboratory-based high-throughput systems, hospital-based instruments, and increasingly compact point-of-care devices capable of delivering results in minutes to hours rather than days. Commercial platforms now cover a wide range of infectious diseases, including respiratory infections like influenza and SARS-CoV-2, HIV, tuberculosis, hepatitis, and sexually transmitted infections, with continued expansion into neglected tropical diseases.

• •Molecular diagnostic methods detect pathogen genetic material rather than antigens or antibodies, enabling earlier and more precise identification of infectious agents
• •The market has matured considerably since the early 2000s, accelerated significantly by the COVID-19 pandemic which drove massive investment in molecular testing infrastructure and supply chains
• •Products range from large centralized laboratory analyzers processing hundreds of samples daily to handheld cartridges suitable for use in clinics, pharmacies, and remote field settings

The escalating global threat of antimicrobial resistance is a primary driver, as rapid molecular diagnostics enable clinicians to prescribe targeted antibiotic therapy rather than broad-spectrum drugs, helping to slow resistance development. The global push for healthcare decentralization is fueling demand for point-of-care molecular devices that deliver laboratory-grade results outside traditional hospital settings, particularly in resource-limited environments. Additional momentum comes from continued product innovation, including isothermal amplification techniques that reduce equipment requirements and next-generation sequencing approaches that enable comprehensive pathogen detection and surveillance.

• •A 2025 comprehensive review estimated the infectious disease point-of-care diagnostics submarket at $12-15 billion, reflecting rapid expansion driven by decentralization needs
• •WHO member state national action plans increasingly integrate both laboratory-based and point-of-care molecular diagnostics as a core strategy against antimicrobial resistance
• •Next-generation sequencing and multiplex PCR platforms are cited as essential growth areas, enabling simultaneous detection of multiple pathogens in a single test

By product type, the market includes reagents and consumables, which typically represent the largest revenue share due to recurring use, along with instruments and associated software for data analysis and reporting. From a technology standpoint, PCR-based methods remain dominant, though isothermal amplification and next-generation sequencing are gaining share due to their speed and breadth of detection. Geographically, North America holds the largest market share, supported by advanced healthcare infrastructure, favorable reimbursement policies, and high testing volumes; however, the Asia-Pacific region is expected to see the fastest growth due to rising healthcare investment, large populations, and increasing burden of infectious diseases.

• •Reagents and test kits constitute the largest product segment, benefiting from repeat usage across high-volume testing scenarios
• •Centralized laboratory settings currently dominate testing volume, though point-of-care molecular diagnostics represent the fastest-growing segment
• •Low- and middle-income countries face systematic procurement and infrastructure challenges, but growing donor funding and government commitments are expanding access

What are the recent trends and outlook?

The convergence of molecular diagnostics with digital technologies, including artificial intelligence for result interpretation and connected platforms for test management, is reshaping how laboratories and clinics operate. Continued miniaturization is producing increasingly portable and affordable devices suitable for use in community health centers, pharmacies, and even home settings. Looking forward, sustained investment in pandemic preparedness infrastructure, combined with growing emphasis on antimicrobial resistance stewardship programs worldwide, should underpin stable long-term demand for molecular infectious disease testing across both developed and emerging markets.

• •Artificial intelligence and machine learning are being integrated into molecular diagnostic platforms for automated result interpretation, reducing operator burden and improving consistency
• •Integrated sample-to-answer cartridges that combine extraction, amplification, and detection in a single sealed unit are gaining adoption for their ease of use and reduced contamination risk
• •The global biosensor-based infectious disease diagnostics segment, which overlaps with molecular technologies, is projected to grow at approximately 6% annually through 2030